Tapentadol IR + Oxycodone IR
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Substance Abuse Detection
Conditions
Substance Abuse Detection
Trial Timeline
Feb 1, 2010 → Feb 1, 2012
NCT ID
NCT01545778About Tapentadol IR + Oxycodone IR
Tapentadol IR + Oxycodone IR is a pre-clinical stage product being developed by Johnson & Johnson for Substance Abuse Detection. The current trial status is completed. This product is registered under clinical trial identifier NCT01545778. Target conditions include Substance Abuse Detection.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01545778 | Pre-clinical | Completed |
Competing Products
5 competing products in Substance Abuse Detection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2 | 52 |
| Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa] | Gilead Sciences | Pre-clinical | 22 |
| RDC-0313 + Buprenorphine + Placebo | Alkermes | Phase 1 | 30 |
| naltrexone for extended release injectable suspension | Alkermes | Approved | 82 |
| modafinil | Pacific Biosciences | Phase 2 | 44 |